These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25818840)

  • 1. Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation.
    Liu YC; Chien SH; Fan NW; Hu MH; Gau JP; Liu CJ; Yu YB; Liu CY; Hsiao LT; Liu JH; Chiou TJ; Tzeng CH
    Br J Haematol; 2015 Jun; 169(5):737-45. PubMed ID: 25818840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large pericardial effusion as a life-threatening complication after hematopoietic stem cell transplantation-association with chronic GVHD in late-onset adult patients.
    Liu YC; Gau JP; Hong YC; Yu YB; Hsiao LT; Liu JH; Chiou TJ; Chen PM; Tzeng CH
    Ann Hematol; 2012 Dec; 91(12):1953-8. PubMed ID: 22869091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pericardial effusion and cardiac tamponade in pediatric stem cell transplant recipients.
    Rhodes M; Lautz T; Kavanaugh-Mchugh A; Manes B; Calder C; Koyama T; Liske M; Parra D; Frangoul H
    Bone Marrow Transplant; 2005 Jul; 36(2):139-44. PubMed ID: 15908968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant.
    Labrador J; López-Corral L; Vazquez L; Sánchez-Guijo F; Guerrero C; Sánchez-Barba M; Lozano FS; Alberca I; Del Cañizo MC; Caballero D; González-Porras JR
    Br J Haematol; 2015 Jun; 169(5):719-25. PubMed ID: 25817436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Affecting Survival in Children With Pericardial Effusion After Hematopoietic Stem Cell Transplantation.
    Jaing TH; Chen SH; Wen YC; Chang TY; Tsai DY; Chung HT; Tsay PK
    Cell Transplant; 2017 Nov; 26(11):1792-1797. PubMed ID: 29338379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective study of risk factors for pericardial effusion after haematopoietic stem cell transplantation in children.
    Tong K; Meng Y; Zhang L; Lei X; Guan X; Xiao L; Yu J; Dou Y
    Hematology; 2023 Dec; 28(1):2245259. PubMed ID: 37551721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and Outcome of Pericardial Effusion in Pediatric Patients After Hematopoietic Stem Cell Transplant: A Single-institution Experience.
    Diamond M; Ruiz-Mesa C; Corrales-Medina FF; Tamariz LJ; Ziga E; Swaminathan S
    J Pediatr Hematol Oncol; 2018 Mar; 40(2):132-136. PubMed ID: 28945662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors for and the Prognostic Impact of Pericardial Effusion after Allogeneic Hematopoietic Stem Cell Transplantation.
    Kubo H; Imataki O; Fukumoto T; Oku M; Ishida T; Kubo YH; Kida JI; Uemura M; Fujita H; Ohno H; Ide M; Ohnishi H; Kadowaki N
    Transplant Cell Ther; 2021 Nov; 27(11):949.e1-949.e8. PubMed ID: 34333179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates.
    Zhang XH; Xu LP; Liu DH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Wang Y; Zhao T; Chen Y; Fu HX; Liu KY; Huang XJ
    Clin Transplant; 2013; 27(1):80-9. PubMed ID: 22938074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pericardial effusion following hematopoietic stem cell transplantation in children: Incidence, risk factors, and outcomes.
    Tinianow A; Gay JC; Bearl DW; Connelly JA; Godown J; Kitko CL
    Pediatr Transplant; 2020 Aug; 24(5):e13748. PubMed ID: 32485042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors and Outcome of Pericardial Effusion After Hematopoietic Stem Cell Transplantation in Children.
    Versluys AB; Grotenhuis HB; Boelens MJJ; Mavinkurve-Groothuis AMC; Breur JMPJ
    Pediatr Cardiol; 2018 Feb; 39(2):236-244. PubMed ID: 29058031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.
    Martínez-Bravo MJ; Calderón-Cabrera C; Márquez-Malaver FJ; Rodríguez N; Guijarro M; Espigado I; Núñez-Roldán A; Pérez-Simón JA; Aguilera I
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1356-62. PubMed ID: 24844856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
    Matin A; Smith BH; Mangaonkar A; Duffy DJ; Wolf R; Alkhateeb H; Shah MV; Hogan WJ; Litzow MR
    Transplant Cell Ther; 2023 May; 29(5):324.e1-324.e6. PubMed ID: 36682472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pericardial effusion after pediatric hematopoietic cell transplant.
    Aldoss O; Gruenstein DH; Bass JL; Steinberger J; Zhang Y; Defor TE; Tolar J; Verneris MR; Orchard PJ
    Pediatr Transplant; 2013 May; 17(3):294-9. PubMed ID: 23464863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation.
    Liu YC; Chien SH; Fan NW; Hu MH; Gau JP; Liu CJ; Yu YB; Liu CY; Hsiao LT; Liu JH; Chiou TJ; Chen PM; Tzeng CH
    J Microbiol Immunol Infect; 2016 Aug; 49(4):567-74. PubMed ID: 25735797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pericardial Effusion Following Hematopoietic Cell Transplantation in Children and Young Adults Is Associated with Increased Risk of Mortality.
    Cox K; Punn R; Weiskopf E; Pinsky BA; Kharbanda S
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1165-1169. PubMed ID: 28390986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
    Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
    Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.